10x Genomics, Inc. (NASDAQ:TXG) Shares Bought by Ieq Capital LLC

Ieq Capital LLC raised its holdings in shares of 10x Genomics, Inc. (NASDAQ:TXG) by 47.2% in the 4th quarter, HoldingsChannel.com reports. The fund owned 158,112 shares of the company’s stock after buying an additional 50,722 shares during the quarter. Ieq Capital LLC’s holdings in 10x Genomics were worth $2,270,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also made changes to their positions in the business. Capital Performance Advisors LLP acquired a new position in shares of 10x Genomics in the 3rd quarter valued at $35,000. Blue Trust Inc. grew its position in shares of 10x Genomics by 136.5% in the third quarter. Blue Trust Inc. now owns 1,776 shares of the company’s stock valued at $40,000 after purchasing an additional 1,025 shares during the period. Sound Income Strategies LLC increased its stake in shares of 10x Genomics by 65.2% during the fourth quarter. Sound Income Strategies LLC now owns 3,370 shares of the company’s stock worth $48,000 after purchasing an additional 1,330 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. purchased a new stake in 10x Genomics during the 4th quarter worth approximately $52,000. Finally, Venturi Wealth Management LLC raised its stake in 10x Genomics by 1,108.9% in the 3rd quarter. Venturi Wealth Management LLC now owns 2,442 shares of the company’s stock valued at $55,000 after purchasing an additional 2,240 shares during the last quarter. 84.68% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research firms have commented on TXG. Canaccord Genuity Group cut their price objective on shares of 10x Genomics from $20.00 to $18.00 and set a “buy” rating for the company in a report on Thursday, February 13th. JPMorgan Chase & Co. cut their target price on 10x Genomics from $14.00 to $12.00 and set a “neutral” rating for the company in a research note on Thursday, February 13th. Stifel Nicolaus decreased their price objective on shares of 10x Genomics from $21.00 to $18.00 and set a “buy” rating on the stock in a report on Thursday, February 13th. Barclays decreased their target price on 10x Genomics from $19.00 to $18.00 and set an “overweight” rating on the stock in a research note on Monday, February 10th. Finally, Leerink Partnrs cut shares of 10x Genomics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, February 13th. One research analyst has rated the stock with a sell rating, nine have issued a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, 10x Genomics presently has a consensus rating of “Hold” and an average target price of $20.57.

10x Genomics Trading Down 5.7 %

NASDAQ TXG opened at $10.90 on Monday. The stock has a market capitalization of $1.33 billion, a price-to-earnings ratio of -7.17 and a beta of 1.85. The business’s 50 day moving average is $14.31 and its two-hundred day moving average is $17.08. 10x Genomics, Inc. has a 12-month low of $10.80 and a 12-month high of $48.42.

10x Genomics (NASDAQ:TXG) last issued its quarterly earnings data on Wednesday, February 12th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.32) by ($0.08). 10x Genomics had a negative return on equity of 25.40% and a negative net margin of 29.90%. Equities analysts forecast that 10x Genomics, Inc. will post -1.43 earnings per share for the current fiscal year.

About 10x Genomics

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.